comparemela.com
Home
Live Updates
BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial : comparemela.com
BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial
BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a,...
Related Keywords
Anne Phelan ,
Stephen Gunnion ,
,
Biomarker Qualification ,
comparemela.com © 2020. All Rights Reserved.